Search research articles
Contact Us
Filters
Showing results (1-10 of 227) with videos related to
Page
of 23
Sort By:
Kidney International. Supplement
|
October 16, 2004
Albuminuria as a surrogate marker for drug development: a European Regulatory perspective
Gonzalo Calvo, Fernando de Andres-Trelles
The Canadian Journal of Cardiology
|
September 19, 2020
Going the Long Noncoding RNA Way Toward Cardiac Regeneration: Mapping Candidate Long Noncoding RNA Controllers of Regeneration
David de Gonzalo-Calvo, Christian Bär
Medicina Clinica
|
February 9, 2006
[Methodological recommendations of the Regulatory Agencies]
Ferran Torres, Gonzalo Calvo, Caridad Pontes
European Heart Journal
|
July 31, 2018
Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles
David de Gonzalo-Calvo, Thomas Thum
Current Drug Discovery Technologies
|
August 16, 2011
Clinical drug development in thromboembolic diseases: regulatory and methodological approach
Gonzalo Calvo-Rojas, Antonio Gómez-Outes
Revista Espanola De Enfermedades Digestivas
|
April 3, 2014
Biosimilar therapy for inflammatory bowel disease
Cristina Avendaño-Solá, Julià Panés, Gonzalo Calvo
Trends in Molecular Medicine
|
June 14, 2022
Methodological considerations for circulating long noncoding RNA quantification
David de Gonzalo-Calvo, Miron Sopić, Yvan Devaux, et al.
Epigenomics
|
January 15, 2019
Circulating miRNAs as mediators in cell-to-cell communication
Christian Bär, Thomas Thum, David de Gonzalo-Calvo
Gaceta Sanitaria
|
October 26, 2005
[Comment. The role of regulatory agencies in the evaluation of drug safety: speaking about of selective serotonin receptor inhibitors]
Francisco J de Abajo, Dolores Montero, Gonzalo Calvo
Clinical Chemistry and Laboratory Medicine
|
May 15, 2024
Navigating the path of reproducibility in microRNA-based biomarker research with ring trials
Miron Sopić, Yvan Devaux, David de Gonzalo-Calvo
Page
of 23
Search research articles
Search
Showing results (1-10 of 227) with videos related to
Sort By:
Page
of 23
Kidney International. Supplement
|
October 16, 2004
Albuminuria as a surrogate marker for drug development: a European Regulatory perspective
Gonzalo Calvo, Fernando de Andres-Trelles
The Canadian Journal of Cardiology
|
September 19, 2020
Going the Long Noncoding RNA Way Toward Cardiac Regeneration: Mapping Candidate Long Noncoding RNA Controllers of Regeneration
David de Gonzalo-Calvo, Christian Bär
Medicina Clinica
|
February 9, 2006
[Methodological recommendations of the Regulatory Agencies]
Ferran Torres, Gonzalo Calvo, Caridad Pontes
European Heart Journal
|
July 31, 2018
Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles
David de Gonzalo-Calvo, Thomas Thum
Current Drug Discovery Technologies
|
August 16, 2011
Clinical drug development in thromboembolic diseases: regulatory and methodological approach
Gonzalo Calvo-Rojas, Antonio Gómez-Outes
Revista Espanola De Enfermedades Digestivas
|
April 3, 2014
Biosimilar therapy for inflammatory bowel disease
Cristina Avendaño-Solá, Julià Panés, Gonzalo Calvo
Trends in Molecular Medicine
|
June 14, 2022
Methodological considerations for circulating long noncoding RNA quantification
David de Gonzalo-Calvo, Miron Sopić, Yvan Devaux, et al.
Epigenomics
|
January 15, 2019
Circulating miRNAs as mediators in cell-to-cell communication
Christian Bär, Thomas Thum, David de Gonzalo-Calvo
Gaceta Sanitaria
|
October 26, 2005
[Comment. The role of regulatory agencies in the evaluation of drug safety: speaking about of selective serotonin receptor inhibitors]
Francisco J de Abajo, Dolores Montero, Gonzalo Calvo
Clinical Chemistry and Laboratory Medicine
|
May 15, 2024
Navigating the path of reproducibility in microRNA-based biomarker research with ring trials
Miron Sopić, Yvan Devaux, David de Gonzalo-Calvo
Page
of 23